IL17A and hepatocellular carcinoma: Notably, this study was performed in an in vivo model of HCC and demonstrated a significant tumor reduction within the treated mice by downregulating the interleukin 17 (IL-17) expression and further weakening the angiogenesis (Figure 4) (230).